Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Myostatin is a paracrine myokine that regulates muscle mass in a variety of species, including humans. In this work, we report a functional role for myostatin as an endocrine hormone that directly promotes pituitary follicle-stimulating hormone (FSH) synthesis and thereby ovarian function in mice. Previously, this FSH-stimulating role was attributed to other members of the transforming growth factor-β family, the activins. Our results both challenge activin's eponymous role in FSH synthesis and establish an unexpected endocrine axis between skeletal muscle and the pituitary gland. Our data also suggest that efforts to antagonize myostatin to increase muscle mass may have unintended consequences on fertility.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199281 | PMC |
| http://dx.doi.org/10.1126/science.adi4736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relugolix for Metastatic Hormone-sensitive Prostate Cancer with Impending Paraplegia.
Ann Afr Med
September 2025
Department of Pathology, Dr. Lal Path Labs, New Delhi, India.
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.
View Article and Find Full Text PDFA single blood luteinizing hormone level of triptorelin stimulation test can diagnose hypothalamic-pituitary-gonadal axis activation in girls with high body mass index.
Front Pediatr
August 2025
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.
Methods: This was a hospital data-based retrospective study.
Orthogonal design-based investigation of dose, time point, and treatment course on the toxicity-efficacy transition of triptolide in collagen-induced arthritis mice.
Front Pharmacol
August 2025
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
In recent years, the potential application of Hook f. (TWHF) in the treatment of rheumatoid arthritis (RA) has garnered increasing attention in both academic research and clinical practice. However, the effective use of is limited in clinical practice by its severe toxic side effects.
View Article and Find Full Text PDFImpact of gonadotropin genetic profile and ovarian reserve on controlled ovarian stimulation: data from prospective cohort of the GENOCS trial.
Front Endocrinol (Lausanne)
September 2025
Gynecology/Obstetrics Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Introduction: Several studies indicate that a specific genotype profile could influence ovarian sensitivity to exogenous gonadotropin. However, most of the previous studies were observational and retrospective and thereby more prone to bias. The aim of this study was to evaluate the impact of gonadotropin single nucleotide polymorphisms (SNPs) on the outcomes of fertilization (IVF) in infertile patients undergoing their first ovarian stimulation (OS) cycle.
View Article and Find Full Text PDFCase Report: Hypergonadotropic hypogonadism in an elite athlete with variant in FSH receptor gene-clinical and sports implications of proper diagnosis.
Front Endocrinol (Lausanne)
September 2025
Department of Pharmacology, Wrocław Medical University, Wrocław, Poland.
Hypergonadotropic hypogonadism is usually caused by the impairment of the structure and function of the gonads, but there are cases caused by reduced stimulation by the follicle-stimulating hormone (FSH) as a result of abnormal variants of genes encoding the follicle-stimulating hormone or its receptor (FSHR). We present the case of an elite athlete with the c.2039A>G variant in one allele of the FSHR gene resulting in hypergonadotropic hypogonadism, low testicular volume, and reduced semen parameters, placing particular emphasis on the diagnostic process and the importance of correct diagnosis in the context of possible treatment with gonadotropins, which can significantly improve fertility, increase testosterone levels, and, in the case of athletes, obtain approval from the anti-doping organization for treatment that increases testosterone levels.
View Article and Find Full Text PDF